EVADER(TM) Gene Delivery Platform for Gene Therapy

Addressing the limitations of other gene delivery platform technologies.

Recent breakthroughs in gene therapy save lives, but there's still a long way to go. EVADER™, Chameleon's next generation, AAV based technology is the next generation gene therapy.

immune

Minimal Immune Response

Current treatments fail when the patient’s immune system attacks the gene therapy.

 

syringes

REPEAT DOSING

With reduced immune response from initial treatment, additional doses may be given to potentially boost immediate response or maintain longer term disease correction.

 

bottle

Increased POtency

Evading attack by the immune system, each dose may be more effective.

 

Every child with a genetic disorder deserves a safe and effective treatment.

8
MILLION CHILDREN PER YEAR

born with serious genetic disorders*

world map made of people

*March of Dimes Report: https://www.marchofdimes.org/mission/march-of-dimes-global-report-on-birth-defects.aspx accessed on April 21, 2021

Current gene therapies offer hope but have limitations:

20-30%
OF INFANT FATALITIES

born with serious genetic disorders

CHILDREN ARE OFTEN EXCLUDED

from gene therapy

UP TO
50%
OF ADULTS

can't be treated

We see a brighter future.

Belle

Niemann-Pick Type C Disease
(Childhood Alzheimer's)

Belle was diagnosed on March 10, 2016. Her family quickly rallied and found a promising clinical trial for the disease. The drug VTS-270 is not a cure but treats the symptoms, which include gradually losing the ability to think, hear, walk, talk and eat on her own.

Marian

Niemann-Pick Type C Disease
(Childhood Alzheimer's)

Marian has been on VTS-270 for Moore than half of her life. She takes ballet, goes to preschool, adores her sister, and loves swimming, laughing with her friends and learning. For Marian and others with NPC, developing more genetic therapies means they can have a future. It means life.

Abby

Niemann-Pick Type C Disease
(Childhood Alzheimer's)

Belle's younger sister, Abby, was also diagnosed just a few short weeks after Belle's diagnosis. Abby did not qualify for the clinical trial, however she was granted compassionate use of the drug. So far, she hasn't shown any symptoms.

We want to make sure every Belle, Marian, and Abby has the chance to learn to read, take driving lessons, get their first jobs, and live the healthy life they choose.

diseases2-800px-noicons

Hematological Disorders

Severe Hemophilia A

Severe Hemophilia B

Musculoskeletal Disorders

Duchenne Muscular Dystrophy

Limb Girdle Muscular Dystrophy

Mitochondrial Disorders

MNGIE

Central Nervous System Disorders

Huntington’s Disease

Lysosomal Storage Disorders

Niemann-Pick Type C (“Childhood Alzheimers”)

Pompe Disease

POTENTIAL TARGETS

Meeting significant unmet needs.

Our platform technology has broad applicability across types of disorders. We anticipate that our treatment could effectively address these types of conditions within the next five years.